ChemoSensitivity Assay Guided Metronomic Chemotherapy Is Safe and Effective for Treating Advanced Pancreatic Cancer.
ChemoSensitivity Assay Guided Metronomic Chemotherapy Is Safe and Effective for Treating Advanced Pancreatic Cancer.
复制标题
化疗敏感性检测指导下的节拍式化疗治疗晚期胰腺癌安全且有效。
DOI：
10.3390/cancers14122906
复制
发表时间：
2022-06-13
期刊：
影响因子：
5.2
通讯作者：
Yu, Kenneth H.
中科院分区：
文献类型：
--
作者：
Isacoff, William H.;Cooper, Brandon;Bartlett, Andrew;McCarthy, Brian;Yu, Kenneth H.
关键词：
迫切需要创新的化疗方案和工具来指导晚期胰腺癌的治疗。我们介绍了一项研究的结果，该研究结合了创新的节律化疗策略和基于血液的药物基因组学工具来指导有效的药物治疗。这项研究为指导节律化疗治疗胰腺癌提供了原则性证据。细胞毒性化疗仍然是晚期胰腺癌(PDAC)的主要治疗方法。新出现的研究支持节律化疗(MCT)是有效的，对现有的剂量和时间表范例提出了挑战。基于血液的药敏试验已被证明可以预测接受标准化疗的晚期PDAC患者的反应和生存。目前的研究结合了这些概念，以实现高度个性化的治疗方法。这是一项回顾分析；研究了飞行员(n=50)和验证队列(n=45)。化疗敏感性分析在基线和治疗期间进行；结果与所用药物和患者结果相关。MCT根据化验结果由治疗医生自行决定。与历史对照组(中位总生存期(MOS)16.8个月)相比，试点队列中的患者获得了良好的生存。与药敏预测结果接近的患者相比，治疗接近匹配的患者在治疗路线上的中位时间(5.3mo比3.3mo，p=0.02)有延长的趋势(20.9mo比12.5mo，p=0.055)。这些发现在验证队列中得到了证实。总体而言，接受MCT密切匹配检测结果的患者经历了27.7个月的显著MOS。化疗药敏分析指导的MCT是晚期PDAC个体化治疗的一种有前途的方法。
Innovative chemotherapy regimens and tools to guide therapy in advanced pancreatic cancer are greatly needed. We present results of a study combining an innovative, metronomic chemotherapy strategy together with a blood-based pharmacogenomic tool to guide effective drug therapy. This study provides proof of principle that guided, metronomic chemotherapy for treatment of pancreatic cancer is a promising approach. Cytotoxic chemotherapy remains the mainstay of treatment for advanced pancreatic adenocarcinoma (PDAC). Emerging studies support metronomic chemotherapy (MCT) as effective, challenging established paradigms of dosing and schedules. The blood-based ChemoSensitivity Assay has been shown to predict response and survival in advanced PDAC patients treated with standard chemotherapy. The current study combines these concepts for a highly personalized treatment approach. This was a retrospective analysis; a pilot (n = 50) and validation cohort (n = 45) were studied. The ChemoSensitivity Assay was performed at baseline and during therapy; results were correlated to drugs administered and patient outcomes. MCT was administered based on the assay results at the treating physician′s discretion. Patients in the pilot cohort experienced favorable survival compared with historical controls (median overall survival (mOS) 16.8 mo). Patients whose treatment closely matched the ChemoSensitivity Assay predictions experienced longer median time on lines of therapy (5.3 vs. 3.3 mo, p = 0.02) and showed a trend for longer mOS (20.9 vs. 12.5 mo, p = 0.055) compared with those not closely matched. These findings were confirmed in the validation cohort. Overall, patients treated with MCT closely matching Assay results experienced a remarkable mOS of 27.7 mo. ChemoSensitivity profiling-guided MCT is a promising approach for personalized therapy in advanced PDAC.
登录
查看更多内容
影响因子：
5.4
作者：
Isacoff WH;Reber HA;Bedford R;Hoos W;Rahib L;Upfill-Brown A;Donahue T;Hines OJ
通讯作者：
Hines OJ
DOI：
10.1007/978-1-60761-416-6_12
发表时间：
2010-01-01
期刊：
MULTI-DRUG RESISTANCE IN CANCER
影响因子：
--
作者：
Ross, Douglas D.;Nakanishi, Takeo
通讯作者：
Nakanishi, Takeo
DOI：
10.1056/nejmoa0804525
发表时间：
2008-11-06
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hoshida Y;Villanueva A;Kobayashi M;Peix J;Chiang DY;Camargo A;Gupta S;Moore J;Wrobel MJ;Lerner J;Reich M;Chan JA;Glickman JN;Ikeda K;Hashimoto M;Watanabe G;Daidone MG;Roayaie S;Schwartz M;Thung S;Salvesen HB;Gabriel S;Mazzaferro V;Bruix J;Friedman SL;Kumada H;Llovet JM;Golub TR
通讯作者：
Golub TR
影响因子：
6.4
作者：
Lu, Janice;Fan, Tina;Zhao, Qiang;Zeng, Wei;Zaslavsky, Eva;Chen, John J.;Frohman, Michael A.;Golightly, Marc G.;Madajewicz, Stefan;Chen, Wen-Tien
通讯作者：
Chen, Wen-Tien
影响因子：
4.7
作者：
Fan, Tina;Zhao, Qiang;Chen, John J.;Chen, Wen-Tien;Pearl, Michael L.
通讯作者：
Pearl, Michael L.